Business Impact Risk from COVID-19
First written in FY2020-Q3. 4 of 10 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2023.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023MitigatedAnnual report
「During the fiscal year, the global economy continued to show signs of recovery as economic activity recovered from the severe conditions caused by the COVID-19 pandemic.」
The recovery in economic activity from the severe business environment caused by the pandemic continued, and the Company described an environment in which the impact on the business through the previous fiscal year was decreasing. - FY2023-Q2MitigatedAnnual report
「During the cumulative second quarter, the global economy continued to show signs of recovery as economic activity recovered from the severe conditions caused by the COVID-19 pandemic.」
Economic activity recovered from the severe business environment caused by COVID-19, reaffirming the assumption that the impact of the pandemic would decrease from the previous fiscal year. - FY2022-Q2MitigatedAnnual report
「In the gastrointestinal endoscopy field, recovery from the impact of COVID-19 resulted in year-on-year growth in all regions, with particularly strong increases in revenue in North America, Europe and Japan.」
Although the impact of COVID-19 remained, case volumes, sales activities and capital investment recovered across the endoscopy, therapeutic devices and scientific businesses, reducing the impact on results from the previous fiscal year. - FY2022-Q1MitigatedAnnual report
「Operating profit in the endoscope business increased, mainly due to higher revenue accompanying the recovery from the impact of COVID-19, despite the recognition of an impairment loss of approximately ¥1.7 billion on an equity-method investment in a European equity-method affiliate.」
Although the impact of COVID-19 remained uncertain, recovery in case volumes, sales activities and capital investment in the healthcare and scientific businesses was reflected in higher revenue and profit, and the impact decreased from the previous fiscal year. - FY2021Update on Full-Year ImpactAnnual report
「The impact on the consolidated results of the Company for the fiscal year was recognized as approximately ¥32.4 billion in revenue from continuing operations.」
The full-year impact of COVID-19 on revenue from continuing operations was updated to approximately ¥32.4 billion. - FY2021-Q3Impact amount updatedAnnual report
「The impact of COVID-19 on the consolidated results of the Company for the cumulative third quarter was recognized as approximately ¥39.0 billion in revenue from continuing operations and approximately ¥3.0 billion in operating profit from continuing operations.」
The impact of COVID-19 for the cumulative third quarter was updated to approximately ¥39.0 billion in revenue from continuing operations and approximately ¥3.0 billion in operating profit. - FY2021-Q2WorsenedAnnual report
「The impact of COVID-19 on the consolidated results of the Company for the cumulative second quarter was recognized as approximately ¥46.0 billion in revenue from continuing operations and approximately ¥13.0 billion in operating profit from continuing operations.」
The impact of COVID-19 expanded from approximately ¥34.0 billion in revenue and approximately ¥11.0 billion in operating profit in FY2021-Q1 to approximately ¥46.0 billion in revenue and approximately ¥13.0 billion in operating profit on a first-half cumulative basis. - FY2021-Q1WorsenedAnnual report
「The impact of COVID-19 on the consolidated results of the Company for the cumulative first quarter was recognized as approximately ¥34.0 billion in revenue and approximately ¥11.0 billion in operating profit.」
The impact of COVID-19 became more concrete than in the previous fiscal year, taking the form of lower revenue across all businesses, constraints on promotional activities, and declines of approximately ¥34.0 billion in revenue and approximately ¥11.0 billion in operating profit. - FY2020MaterialisedAnnual report
「The business activities of the Company Group have been affected by restrictions on visits to customers, including medical institutions, and by the postponement or cancellation of business meetings.」
The COVID-19 risk materialized in the form of restrictions on visits to medical institutions, a decline in the number of cases, the postponement or cancellation of business meetings, working from home, and the postponement of earnings announcements and general meetings of shareholders. The impact on company-wide results was stated as approximately ¥13.0 billion in revenue and approximately ¥8.0 billion in operating profit. - FY2020-Q3First statedAnnual report
「Since multiple cases of COVID-19 were first reported in Wuhan, Hubei Province, the People’s Republic of China, in December 2019, reports of cases have continued around the world. In addition, the World Health Organization (WHO) Emergency Committee announced at the end of January 2020 that the outbreak constituted a “public health emergency of international concern.” Depending on how the situation develops, it may affect the business activities of the Company Group and its ability to secure earnings.」
In light of the outbreak of COVID-19 and the WHO’s declaration of a public health emergency, the potential impact on business activities and earnings generation was identified as a new risk.